Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Prognostic Impact of Phosphorylated Discoidin Domain Receptor-1 in Esophageal Cancer.

Sugimoto K, Ito T, Woo J, Tully E, Sato K, Orita H, Brock MV, Gabrielson E.

J Surg Res. 2019 Mar;235:479-486. doi: 10.1016/j.jss.2018.10.032. Epub 2018 Nov 26.

PMID:
30691832
2.

Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer.

Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone KA, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE.

Cancer Res. 2018 Dec 12. pii: canres.1127.2018. doi: 10.1158/0008-5472.CAN-18-1127. [Epub ahead of print]

PMID:
30541742
3.

Endoscopic thoracic sympathectomy for primary focal hyperhidrosis: impact on psycho-social symptomatology and psychotropic medication use.

Li DC, Hulbert A, Waldbaum B, Ober C, Hooker CM, Huang P, Molena D, Yang SC, Ito T, Perry-Parrish C, Brock MV.

Eur J Cardiothorac Surg. 2018 Nov 1;54(5):904-911. doi: 10.1093/ejcts/ezy211.

PMID:
29860276
4.

Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer.

Chen M, Nie J, Liu Y, Li X, Zhang Y, Brock MV, Feng K, Wu Z, Li X, Shi L, Li S, Guo M, Mei Q, Han W.

Int J Cancer. 2018 Sep 15;143(6):1530-1540. doi: 10.1002/ijc.31531. Epub 2018 Apr 26.

5.

Non-blood circulating tumor DNA detection in cancer.

Peng M, Chen C, Hulbert A, Brock MV, Yu F.

Oncotarget. 2017 Aug 4;8(40):69162-69173. doi: 10.18632/oncotarget.19942. eCollection 2017 Sep 15. Review.

6.

The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer.

Zhang Y, Mei Q, Liu Y, Li X, Brock MV, Chen M, Dong L, Shi L, Wang Y, Guo M, Nie J, Han W.

Oncoimmunology. 2017 May 17;6(9):e1323619. doi: 10.1080/2162402X.2017.1323619. eCollection 2017.

7.

Meeting Report of the Fifth International Cancer Epigenetics Conference in Beijing, China, October 2016.

Gao D, Herman JG, Cui H, Jen J, Fuks F, Brock MV, Ushijima T, Croce C, Akiyama Y, Guo M.

Epigenomics. 2017 Jul;9(7):937-941. doi: 10.2217/epi-2017-0030. Epub 2017 May 22.

8.

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE.

Cancer Discov. 2017 Mar;7(3):264-276. doi: 10.1158/2159-8290.CD-16-0828. Epub 2016 Dec 28.

9.

Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum.

Hulbert A, Jusue-Torres I, Stark A, Chen C, Rodgers K, Lee B, Griffin C, Yang A, Huang P, Wrangle J, Belinsky SA, Wang TH, Yang SC, Baylin SB, Brock MV, Herman JG.

Clin Cancer Res. 2017 Apr 15;23(8):1998-2005. doi: 10.1158/1078-0432.CCR-16-1371. Epub 2016 Oct 11.

10.

Complex Esophageal Reconstruction Procedures Have Acceptable Outcomes Compared With Routine Esophagectomy.

Moore JM, Hooker CM, Molena D, Mungo B, Brock MV, Battafarano RJ, Yang SC.

Ann Thorac Surg. 2016 Jul;102(1):215-22. doi: 10.1016/j.athoracsur.2016.02.039. Epub 2016 May 21.

PMID:
27217296
11.

Systematic study of target localization for bioluminescence tomography guided radiation therapy.

Yu J, Zhang B, Iordachita II, Reyes J, Lu Z, Brock MV, Patterson MS, Wong JW, Wang KK.

Med Phys. 2016 May;43(5):2619. doi: 10.1118/1.4947481.

12.

Robotic Versus Thoracoscopic Resection for Lung Cancer: Early Results of a New Robotic Program.

Mungo B, Hooker CM, Ho JS, Yang SC, Battafarano RJ, Brock MV, Molena D.

J Laparoendosc Adv Surg Tech A. 2016 Apr;26(4):243-8. doi: 10.1089/lap.2016.0049. Epub 2016 Mar 15.

13.

Methylation of DACT2 accelerates esophageal cancer development by activating Wnt signaling.

Zhang M, Linghu E, Zhan Q, He T, Cao B, Brock MV, Herman JG, Xiang R, Guo M.

Oncotarget. 2016 Apr 5;7(14):17957-69. doi: 10.18632/oncotarget.7647.

14.

DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies.

Pisanic TR 2nd, Athamanolap P, Poh W, Chen C, Hulbert A, Brock MV, Herman JG, Wang TH.

Nucleic Acids Res. 2015 Dec 15;43(22):e154. doi: 10.1093/nar/gkv795. Epub 2015 Aug 24.

15.

Why are patients being readmitted after surgery for esophageal cancer?

Shah SP, Xu T, Hooker CM, Hulbert A, Battafarano RJ, Brock MV, Mungo B, Molena D, Yang SC.

J Thorac Cardiovasc Surg. 2015 May;149(5):1384-9; discussion 1389-91. doi: 10.1016/j.jtcvs.2015.01.064. Epub 2015 Feb 11.

16.

Epigenetic silencing BCL6B induced colorectal cancer proliferation and metastasis by inhibiting P53 signaling.

Hu S, Cao B, Zhang M, Linghu E, Zhan Q, Brock MV, Herman JG, Mao G, Guo M.

Am J Cancer Res. 2015 Jan 15;5(2):651-62. eCollection 2015.

17.

Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.

Li X, Yu J, Brock MV, Tao Q, Herman JG, Liang P, Guo M.

Oncotarget. 2015 May 10;6(13):11547-60.

18.

Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel.

Yun T, Liu Y, Gao D, Linghu E, Brock MV, Yin D, Zhan Q, Herman JG, Guo M.

Genes Cancer. 2015 Jan;6(1-2):38-48.

19.

Does obesity affect the outcomes of pulmonary resections for lung cancer? A National Surgical Quality Improvement Program analysis.

Mungo B, Zogg CK, Hooker CM, Yang SC, Battafarano RJ, Brock MV, Molena D.

Surgery. 2015 Apr;157(4):792-800. doi: 10.1016/j.surg.2014.10.016. Epub 2015 Feb 7.

PMID:
25666333
20.

RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel.

Guo J, Yang Y, Yang Y, Linghu E, Zhan Q, Brock MV, Herman JG, Zhang B, Guo M.

Oncotarget. 2015 Feb 28;6(6):4202-13.

21.

Epigenetic changes and functional study of HOXA11 in human gastric cancer.

Cui Y, Gao D, Linghu E, Zhan Q, Chen R, Brock MV, Herman JG, Guo M.

Epigenomics. 2015;7(2):201-13. doi: 10.2217/epi.14.92. Epub 2015 Jan 15.

PMID:
25590359
22.

DACT2 is frequently methylated in human gastric cancer and methylation of DACT2 activated Wnt signaling.

Yu Y, Yan W, Liu X, Jia Y, Cao B, Yu Y, Lv Y, Brock MV, Herman JG, Licchesi J, Yang Y, Guo M.

Am J Cancer Res. 2014 Nov 19;4(6):710-24. eCollection 2014.

23.

Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling.

Zhao Z, Herman JG, Brock MV, Sheng J, Zhang M, Liu B, Guo M.

PLoS One. 2014 Nov 6;9(11):e112336. doi: 10.1371/journal.pone.0112336. eCollection 2014.

24.

Does neoadjuvant therapy for esophageal cancer increase postoperative morbidity or mortality?

Mungo B, Molena D, Stem M, Yang SC, Battafarano RJ, Brock MV, Lidor AO.

Dis Esophagus. 2015 Oct;28(7):644-51. doi: 10.1111/dote.12251. Epub 2014 Jul 24.

25.

Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer by activating TGF-β signalling.

Yan W, Wu K, Herman JG, Brock MV, Zhou Y, Lu Y, Zhang Z, Yang Y, Guo M.

J Cell Mol Med. 2014 Dec;18(12):2499-511. doi: 10.1111/jcmm.12325. Epub 2014 Jun 9.

26.

Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers.

Hulbert A, Hooker CM, Keruly JC, Brown T, Horton K, Fishman E, Rodgers K, Lee B, Sam C, Tsai S, Weihe E, Pridham G, Drummond B, Merlo C, Geronimo M, Porter M, Cox S, Li D, Harline M, Teran M, Wrangle J, Mudge B, Taylor G, Kirk GD, Herman JG, Moore RD, Brown RH, Brock MV.

J Thorac Oncol. 2014 Jun;9(6):752-9. doi: 10.1097/JTO.0000000000000161.

27.

Predictive value of CHFR and MLH1 methylation in human gastric cancer.

Li Y, Yang Y, Lu Y, Herman JG, Brock MV, Zhao P, Guo M.

Gastric Cancer. 2015 Apr;18(2):280-7. doi: 10.1007/s10120-014-0370-2. Epub 2014 Apr 21.

28.

Silencing DACH1 promotes esophageal cancer growth by inhibiting TGF-β signaling.

Wu L, Herman JG, Brock MV, Wu K, Mao G, Yan W, Nie Y, Liang H, Zhan Q, Li W, Guo M.

PLoS One. 2014 Apr 17;9(4):e95509. doi: 10.1371/journal.pone.0095509. eCollection 2014.

29.

Staging lymph node metastases from lung cancer in the mediastinum.

Terán MD, Brock MV.

J Thorac Dis. 2014 Mar;6(3):230-6. doi: 10.3978/j.issn.2072-1439.2013.12.18. Review.

30.

Epigenetic changes associated with neoplasms of the exocrine and endocrine pancreas.

Guo M, Jia Y, Yu Z, House MG, Esteller M, Brock MV, Herman JG.

Discov Med. 2014 Feb;17(92):67-73.

31.

Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer.

Wrangle J, Machida EO, Danilova L, Hulbert A, Franco N, Zhang W, Glöckner SC, Tessema M, Van Neste L, Easwaran H, Schuebel KE, Licchesi J, Hooker CM, Ahuja N, Amano J, Belinsky SA, Baylin SB, Herman JG, Brock MV.

Clin Cancer Res. 2014 Apr 1;20(7):1856-64. doi: 10.1158/1078-0432.CCR-13-2109. Epub 2014 Jan 31.

32.

Survival after community diagnosis of early-stage non-small cell lung cancer.

Kanarek NF, Hooker CM, Mathieu L, Tsai HL, Rudin CM, Herman JG, Brock MV.

Am J Med. 2014 May;127(5):443-9. doi: 10.1016/j.amjmed.2013.12.023. Epub 2014 Jan 28.

33.

Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.

Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, Tykodi SS, Easton K, Carvajal RD, Jones PA, Laird PW, Weisenberger DJ, Tsai S, Juergens RA, Topalian SL, Rudin CM, Brock MV, Pardoll D, Baylin SB.

Oncotarget. 2013 Nov;4(11):2067-79.

34.

Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer.

Yan W, Wu K, Herman JG, Brock MV, Fuks F, Yang L, Zhu H, Li Y, Yang Y, Guo M.

Epigenetics. 2013 Dec;8(12):1373-83. doi: 10.4161/epi.26781. Epub 2013 Oct 22.

35.

Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008).

Mathieu LN, Kanarek NF, Tsai HL, Rudin CM, Brock MV.

Dis Esophagus. 2014 Nov-Dec;27(8):757-63. doi: 10.1111/dote.12147. Epub 2013 Oct 7.

36.

Epigenetic silencing of CXCL14 induced colorectal cancer migration and invasion.

Cao B, Yang Y, Pan Y, Jia Y, Brock MV, Herman JG, Guo M.

Discov Med. 2013 Oct;16(88):137-47.

37.

Extraction and processing of circulating DNA from large sample volumes using methylation on beads for the detection of rare epigenetic events.

Keeley B, Stark A, Pisanic TR 2nd, Kwak R, Zhang Y, Wrangle J, Baylin S, Herman J, Ahuja N, Brock MV, Wang TH.

Clin Chim Acta. 2013 Oct 21;425:169-75. doi: 10.1016/j.cca.2013.07.023. Epub 2013 Aug 1.

38.

Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD.

Chest. 2013 May;143(5 Suppl):e1S-e29S. doi: 10.1378/chest.12-2345. Review.

39.

Epigenetic regulation of the Wnt signaling inhibitor DACT2 in human hepatocellular carcinoma.

Zhang X, Yang Y, Liu X, Herman JG, Brock MV, Licchesi JD, Yue W, Pei X, Guo M.

Epigenetics. 2013 Apr;8(4):373-82. doi: 10.4161/epi.24113. Epub 2013 Feb 28.

40.

Invited commentary: the etiology of lung cancer in men compared with women.

Alberg AJ, Wallace K, Silvestri GA, Brock MV.

Am J Epidemiol. 2013 Apr 1;177(7):613-6. doi: 10.1093/aje/kws444. Epub 2013 Feb 20.

41.

CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.

Pillai RN, Brodie SA, Sica GL, Shaojin Y, Li G, Nickleach DC, Yuan L, Varma VA, Bonta D, Herman JG, Brock MV, Ribeiro MJ, Ramalingam SS, Owonikoko TK, Khuri FR, Brandes JC.

Clin Cancer Res. 2013 Mar 15;19(6):1603-11. doi: 10.1158/1078-0432.CCR-12-2995. Epub 2013 Feb 5.

42.

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.

Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, Haverty PM, Gentleman R, Chaudhuri S, Janakiraman V, Jaiswal BS, Parikh C, Yuan W, Zhang Z, Koeppen H, Wu TD, Stern HM, Yauch RL, Huffman KE, Paskulin DD, Illei PB, Varella-Garcia M, Gazdar AF, de Sauvage FJ, Bourgon R, Minna JD, Brock MV, Seshagiri S.

Nat Genet. 2012 Oct;44(10):1111-6. doi: 10.1038/ng.2405. Epub 2012 Sep 2.

43.

Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer.

Jia Y, Yang Y, Zhan Q, Brock MV, Zheng X, Yu Y, Herman JG, Guo M.

J Mol Diagn. 2012 Nov;14(6):577-85. doi: 10.1016/j.jmoldx.2012.06.004. Epub 2012 Aug 21.

PMID:
22921431
44.

A handy tool to teach segmental liver anatomy to surgical trainees.

Pauli EM, Staveley-O'Carroll KF, Brock MV, Efron DT, Efron G.

Arch Surg. 2012 Aug;147(8):692-3. doi: 10.1001/archsurg.2012.689. No abstract available.

45.

CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer.

Liu X, Zhang X, Zhan Q, Brock MV, Herman JG, Guo M.

Cancer Biol Ther. 2012 Oct;13(12):1152-7. doi: 10.4161/cbt.21344. Epub 2012 Aug 23.

46.

SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer.

Yin D, Jia Y, Yu Y, Brock MV, Herman JG, Han C, Su X, Liu Y, Guo M.

Discov Med. 2012 Jul;14(74):33-40.

47.

Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer.

Jia Y, Yang Y, Brock MV, Zhan Q, Herman JG, Guo M.

J Pathol. 2013 Jun;230(2):194-204. doi: 10.1002/path.4073.

48.

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.

Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA, Herman JG, Baylin SB, Brock MV, Rudin CM.

Cancer Discov. 2011 Dec;1(7):598-607. doi: 10.1158/2159-8290.CD-11-0214. Epub 2011 Nov 9.

49.

Defining a gene promoter methylation signature in sputum for lung cancer risk assessment.

Leng S, Do K, Yingling CM, Picchi MA, Wolf HJ, Kennedy TC, Feser WJ, Baron AE, Franklin WA, Brock MV, Herman JG, Baylin SB, Byers T, Stidley CA, Belinsky SA.

Clin Cancer Res. 2012 Jun 15;18(12):3387-95. doi: 10.1158/1078-0432.CCR-11-3049. Epub 2012 Apr 17.

50.

Methylation of TFPI-2 is an early event of esophageal carcinogenesis.

Jia Y, Yang Y, Brock MV, Cao B, Zhan Q, Li Y, Yu Y, Herman JG, Guo M.

Epigenomics. 2012 Apr;4(2):135-46. doi: 10.2217/epi.12.11.

Supplemental Content

Loading ...
Support Center